BGP 15

Drug Profile

BGP 15

Alternative Names: BGP-15

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator N-Gene Research Laboratories
  • Developer Allos Therapeutics; N-Gene Research Laboratories; University of Melbourne
  • Class Antihyperglycaemics; Oximes; Piperidines; Small molecules
  • Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors; Oxygen radical formation antagonists; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Duchenne muscular dystrophy

Highest Development Phases

  • Phase II Insulin resistance; Type 2 diabetes mellitus
  • No development reported Duchenne muscular dystrophy
  • Discontinued Chemotherapy-induced damage; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in Australia
  • 20 Aug 2015 BPG 15 is still in phase-II development for Insulin resistance and Type-2 diabetes mellitus in Hungary and USA
  • 20 Aug 2013 BGP 15 is available for licensing as of 19 Apr 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top